Skip to content

Study · Non-randomized trial · n = 20 · 1996

5 results

[Experience with using high doses of cerebrolysin in vascular dementia].

Iakhno NN, Damulin IV, Zakharov VV, Levin OS, Elkin MN

Terapevticheskii arkhiv1 Jan 1996Cited by 2 (Europe PMC)

PMID9026950 (opens in a new tab)PepBankPUB-09026950
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with vascular dementia, high-dose Cerebrolysin was well tolerated.

    In plain wordsIn patients with vascular dementia, high-dose Cerebrolysin was well tolerated.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTolerability
    Study

    n = 20

    Outcome group
    Adverse events · Whole body
    Studied dose
    high-doseAs given in this study (human).

    Source sentences

    Summary
    The drug was well tolerated, affected positively cognitive function, especially neurodynamic processes.
    1 context sentence
    Summary · context
    The efficacy and tolerability of high-dose neurotrophic drug cerebrolysin was studied in 20 patients with vascular dementia diagnosed by criteria NINDS-AIREN and DSM-IV.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with vascular dementia, high-dose Cerebrolysin positively affected cognitive function, especially neurodynamic processes.

    In plain wordsIn patients with vascular dementia, cognitive function improved after high-dose Cerebrolysin, especially neurodynamic processes.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive function
    Study

    n = 20

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    high-doseAs given in this study (human).

    Source sentences

    Summary
    The drug was well tolerated, affected positively cognitive function, especially neurodynamic processes.
    1 context sentence
    Summary · context
    The efficacy and tolerability of high-dose neurotrophic drug cerebrolysin was studied in 20 patients with vascular dementia diagnosed by criteria NINDS-AIREN and DSM-IV.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with vascular dementia, EEG rapid rhythm power increased after Cerebrolysin treatment.

    In plain wordsIn patients with vascular dementia, rapid brain rhythm power increased after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseEEG rapid rhythm power
    Study

    n = 20

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    high-doseAs given in this study (human).

    Source sentences

    Summary
    EEG featured after treatment intensification of rapid rhythms power and a decrease in delta-activity spectrum.
    1 context sentence
    Summary · context
    The efficacy and tolerability of high-dose neurotrophic drug cerebrolysin was studied in 20 patients with vascular dementia diagnosed by criteria NINDS-AIREN and DSM-IV.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with vascular dementia, the EEG delta activity spectrum decreased after Cerebrolysin treatment.

    In plain wordsIn patients with vascular dementia, slow delta brain activity decreased after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEEG delta activity spectrum
    Study

    n = 20

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    high-doseAs given in this study (human).

    Source sentences

    Summary
    EEG featured after treatment intensification of rapid rhythms power and a decrease in delta-activity spectrum.
    1 context sentence
    Summary · context
    The efficacy and tolerability of high-dose neurotrophic drug cerebrolysin was studied in 20 patients with vascular dementia diagnosed by criteria NINDS-AIREN and DSM-IV.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with vascular dementia, Cerebrolysin had its highest effect in those with mild cognitive defects.

    In plain wordsIn patients with vascular dementia, Cerebrolysin had greater effects with mild cognitive defects than with more severe defects.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseEffect by cognitive severity
    Study

    n: not reported in source

    Comparator
    Patients with more severe cognitive defects
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    high-doseAs given in this study (human).

    Source sentences

    Summary
    The highest effect of cerebrolysin was achieved in patients with mild cognitive defects.
    1 context sentence
    Summary · context
    The efficacy and tolerability of high-dose neurotrophic drug cerebrolysin was studied in 20 patients with vascular dementia diagnosed by criteria NINDS-AIREN and DSM-IV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.